Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Tonix Pharmaceuticals Holding Corp TNXP

Healthcare Biotechnology
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TNXP)

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

GlobeNewswire April 1, 2024

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

GlobeNewswire March 28, 2024

Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome

GlobeNewswire March 25, 2024

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

GlobeNewswire March 21, 2024

Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya(TM) for the Management of Fibromyalgia

GlobeNewswire March 20, 2024

Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

GlobeNewswire March 19, 2024

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring

GlobeNewswire March 12, 2024

Tonix Pharmaceuticals Reports Improvement in "Brain Fog," in Fibromyalgia Patients Treated with Tonmya(TM) in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia

GlobeNewswire March 11, 2024

Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

GlobeNewswire March 7, 2024
View More News ››

Opinion & Analysis (NDAQ:TNXP)

Eight ways to leverage the small-cap biotech bull market: Ajay Tandon and Jay Albany of SeeThruEquity

Gail Dutton October 30, 2015
View More Opinion ››

Bullboard Posts (NDAQ:TNXP)

BUY BUY BUY BUY BUY

Im going all in on monday at this price dont know why it went south minus43%
Nibinator - March 31, 2024

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
EllaMae - April 13, 2023

TNXP..... NR's after the open

Seldom workout ; )
Iseneschal - February 2, 2023

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

   
EllaMae - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >>
EllaMae - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

 
EllaMae - June 2, 2022
View more Bullboard ››

Royalties Inc.

Royalties Inc.

Royalties Inc. is focused on seeking cash flow generating royalty opportunities in various industries. While the Issuer’s ...
View More »